Company profile
Aardvark Therapeutics, Inc.
NASDAQ:AARDBiotechnology: Pharmaceutical Preparations
Drug pipeline (1)
| Asset | Stage | Revenue | Trials | Status |
|---|---|---|---|---|
| DENATONIUM ACETATE MONOHYDRATE | phase3 | — | 5 | completed, terminated |
Revenue is the latest reported period from SEC filings. A combination product's amount appears on each of its constituent assets, so those rows are not additive.
Clinical trials (6)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT05153434 | phase2 | completed | 2022-05-27 | 2024-09-24 | Aardvark Therapeutics, Inc. | A Study of Oral ARD-101 in Patients With Prader-Willi Syndrome |
| NCT06126653 | phase2 | completed | 2024-08-01 | 2025-01-13 | Aardvark Therapeutics, Inc. | A Study to Evaluate ARD-501 in Patients With Autism Spectrum Disorder |
| NCT06828861 | phase3 | terminated | 2024-12-20 | 2026-05-07 | Aardvark Therapeutics, Inc. | ARD-101 for Treatment of PWS: The Hunger Elimination or Reduction Objective Trial |
| NCT05215847 | phase2 | completed | 2022-03-01 | 2023-02-03 | Aardvark Therapeutics, Inc. | Study to Evaluate ARD-101 in Adults Receiving Bariatric Surgery |
| NCT05121441 | phase2 | completed | 2021-11-15 | 2022-11-09 | Aardvark Therapeutics, Inc. | Study to Evaluate ARD-101 in Adults With Obesity |
FDA applications (0)
No records yet.